Prelude Capital Management’s Coya Therapeutics COYA Stock Holding History

Prelude Capital Management’s Portfolio COYA Stock Details COYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$399K	Buy	101,330 +49,060	+94%	+$229K	0.03%	604
2025 Q4	$303K	Buy	52,270 +16,500	+46%	+$100K	0.02%	790
2025 Q3	$204K	Hold	35,770	–	–	0.02%	938
2025 Q2	$206K	Hold	35,770	–	–	0.02%	805
2025 Q1	$231K	Hold	35,770	–	–	0.02%	842
2024 Q4	$205K	Hold	35,770	–	–	0.01%	981
2024 Q3	$231K	Hold	35,770	–	–	0.01%	1000
2024 Q2	$217K	Hold	35,770	–	–	0.02%	954
2024 Q1	$355K	Hold	35,770	–	–	0.02%	810
2023 Q4	$265K	Hold	35,770	–	–	0.02%	795
2023 Q3	$137K	Buy	+35,770	New	+$142K	0.01%	961

Other funds holding COYA

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

PMG

Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Prelude Capital Management's COYA Position: Q1 2026 in Review

Prelude Capital Management increased its Coya Therapeutics (COYA) stake by 94% in Q1 2026, buying an estimated $229K and bringing the position to 101,330 shares worth $399K. The position accounts for 0.03% of the portfolio, ranked #604.

Prelude Capital Management first reported a position in COYA in Q3 2023 and has held it in 11 quarters since. 56 funds tracked by Wall St. Rank hold COYA as of Q1 2026.

Prelude Capital Management held 101,330 shares of Coya Therapeutics worth $399K as of Q1 2026.
Prelude Capital Management bought 49,060 Coya Therapeutics shares in Q1 2026, an estimated $229K.
Coya Therapeutics made up 0.03% of Prelude Capital Management's portfolio in Q1 2026, its #604 holding.
Prelude Capital Management first reported a position in Coya Therapeutics in Q3 2023 and has held it in 11 quarters since.
56 funds tracked by Wall St. Rank held Coya Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.